Trial Profile
PHASE 2A, MULTICENTER, SINGLE ARM, OPEN- LABEL, TWO-STAGE, STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06480605 IN SUBJECTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs RVT-3101 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms TUSCANY
- Sponsors Pfizer
- 02 Mar 2022 Results assessing analysis of tissue transcriptomic, peripheral blood proteomic, and fecal metagenomic by using data from this study published in the Inflammatory Bowel Diseases
- 28 Sep 2018 Status changed from recruiting to completed.
- 12 Sep 2018 Planned End Date changed from 30 Aug 2018 to 30 Sep 2018.